A new preliminary study published in Nature suggests that COVID-19 vaccines might actually boost the immune system to make ...

MDX2004 is designed to activate T cells through three unique signalling pathways to enhance immune activation.

Enterome, a clinical-stage biopharmaceutical company developing novel immunotherapies for cancer, has announced that the US ...

A new cancer clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) shows that a drug that utilizes the body’s ...

HTL0039732 (also known as NXE0039732) is Nxera’s novel oral EP4 antagonist with the potential to treat a wide range of ...

A new cancer clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) shows that a drug that utilizes the body's ...

Invikafusp alfa demonstrated significant antitumor activity in TMB-H and MSI-H tumors resistant to immune checkpoint blockade, with ORRs ranging from 20.5% to 33.3%. The trial's safety profile was ...

First patient dosed in Phase 1/2a study with novel immune rejuvenator, a trispecific antibody-fusion protein Two MDX2004 abstracts accepted for poster presentation at SITC Annual Meeting 2025 WESTON, ...

SELLAS Life Sciences Group, Inc. ( SLS) Discusses Innovation in AML Treatments With Focus on GPS and SLS009 Programs October 29, 2025 10:00 AM EDT ...

KEYMAKER-U03 is an international, multicenter, open-label, Phase I/II umbrella trial evaluating experimental combinations of ...

Company will share data demonstrating CD47 overexpression as key predictive biomarker for response with the Company’s lead candidate, evorpacept, ...